Posted by Michael Wonder on 02 Feb 2026
Imfinzi perioperative raegimen recommended for approval in the EU by CHMP for patients with early gastric and gastro-oesophageal cancers
2 February 2026 - Recommendation based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the Imfinzi regimen versus chemotherapy alone.
AstraZeneca’s Imfinzi (durvalumab) in combination with standard of care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been recommended for approval in the European Union for the treatment of adult patients with resectable, early-stage and locally advanced (stages II, III, IVA) gastric and gastro-oesophageal junction cancers.
